Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Sponsored Advancing symptom science at City of Hope and across the globe November 14, 2025Vol.51 No.42By Jeannine M. Brant
FreeIn the Archives How a neuroendocrine cancer survivor fueled 20 years of researchNETRF celebrates 20 years, $40 million in research funding November 14, 2025Vol.51 No.42
PodcastThe Directors The Directors: Ruben Mesa and Kunle Odunsi on how immigration and diversity accelerate discovery“This has always made our environment stronger, not weaker.” November 07, 2025Vol.51 No.41By Jacquelyn Cobb and Paul Goldberg
Regulatory News CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”Cancer advocates express concern about comments that signal trouble for accelerated approval November 07, 2025Vol.51 No.41By Claire Marie Porter and Paul Goldberg
Guest Editorial How George Tidmarsh crossed the FDA-industry Rubicon November 07, 2025Vol.51 No.41By Mikkael A. Sekeres
Guest Editorial How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care November 07, 2025Vol.51 No.41By Kathy Davy
Sponsored City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure November 07, 2025Vol.51 No.41By Ravi Salgia
NCINews Analysis Cancer centers adapt to life without site visits as NIH changes CCSG review October 31, 2025Vol.51 No.40By Paul Goldberg
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal October 31, 2025Vol.51 No.40By Jacquelyn Cobb
